Date | October 18, 2021 |
---|---|
Cause | COVID-19 pandemic |
COVID-19 vaccination in Burundi is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country. Burundi was one of the last nation states in the world to commence vaccination against COVID-19. [1] This was mostly due to the government's refusal to vaccinate the population throughout most of 2021. In February 2021, Thaddee Ndikumana, the health minister of Burundi, said his country was more concerned with prevention measures. "Since more than 95% of patients are recovering, we estimate that the vaccines are not yet necessary," local media reported. [2]
In October 2021, however, the Burundian government announced that it had received delivery of 500,000 doses of the Chinese Sinopharm BIBP vaccine, and announced that it would begin inoculation. [3] Targeted vaccinations subsequently started on 18 October 2021.
This section is empty. You can help by adding to it. (September 2021) |
Burundi received a Chinese donation of 500,000 doses of the Sinopharm BIBP vaccine on 14 October and launched a targeted vaccination programme on 18 October 2021. [4] By the end of the month 560 vaccine doses had been administered.
By the end of the month 1592 vaccine doses had been administered and 778 persons were fully vaccinated.
By the end of the month 6421 vaccine doses had been administered and 4453 persons were fully vaccinated (less than 0.1% of the targeted population).
By the end of the month 8400 vaccine doses had been administered and 6016 persons were fully vaccinated (less than 0.2% of the targeted population).
By the end of the month 11502 vaccine doses had been administered and 9181 persons were fully vaccinated.
By the end of the month 12464 vaccine doses had been administered and 9906 persons were fully vaccinated.
Cumulative vaccinations in Burundi [5]
Graphs are unavailable due to technical issues. There is more info on Phabricator and on MediaWiki.org. |
The Sinopharm BIBP COVID-19 vaccine, also known as BBIBP-CorV, the Sinopharm COVID-19 vaccine, or BIBP vaccine, is one of two whole inactivated virus COVID-19 vaccines developed by Sinopharm's Beijing Institute of Biological Products. It completed Phase III trials in Argentina, Bahrain, Egypt, Morocco, Pakistan, Peru, and the United Arab Emirates (UAE) with over 60,000 participants. BBIBP-CorV shares similar technology with CoronaVac and Covaxin, other inactivated virus vaccines for COVID-19. Its product name is SARS-CoV-2 Vaccine, not to be confused with the similar product name of CoronaVac.
On 22 February 2021, Zimbabwe launched their national COVID-19 vaccination program using the Sinopharm BIBP vaccine. As of 17 June 2022, 6,260,228 people have received their first dose, 4,598,703 have received their second dose, and 851,874 have received a third dose.
On 29 January 2021, Algeria launched a COVID-19 vaccination campaign, a day after receiving its first shipment of 50,000 doses of the Russia's Sputnik V vaccine. As of 6 June 2021, around 2.5 million doses have been administered. Algeria is currently vaccinating its population with both Sputnik V and Oxford-AstraZeneca vaccines.
The COVID-19 vaccination in Morocco is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
COVID-19 vaccination in Angola is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country. As of 15 June 2021, Angola has administered 1,314,375 doses of vaccines.822,109 people with the first dose and 492,266 people fully vaccinated. Angola began their vaccination program shortly after receiving their first shipment of Oxford AstraZeneca vaccine in early March 2021.
COVID-19 vaccination in Botswana is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
On 23 February 2021, Senegal began its national vaccination program against the COVID-19. As of 10 March, 68,205 people in Senegal have been able to be vaccinated.
COVID-19 vaccination programs are ongoing in the majority countries and territories in Africa, with 51 of 54 African countries having launched vaccination programs by July 2021. As of October 2023, 51.8% of the continent's population is fully vaccinated with over 1084.5 million doses administered.
Bhutan has promised a free COVID-19 vaccination to all of its citizens, both inside and outside the country. It started mass vaccinations on 27 March 2021.
COVID-19 vaccination in Nigeria is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country. Vaccination began on 5 March 2021. As of 28 February 2022, 17,914,944 people have received their first dose a COVID-19 vaccine, and 8,197,832 have received their second dose.
COVID-19 vaccination in Sri Lanka is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, in response to the ongoing pandemic in the country. As of late July, the Sinopharm BIBP vaccine accounted for 78% of the total 13.8 million vaccines obtained by Sri Lanka to date. The United States donated over 1.5 million Moderna vaccine through COVAX.
COVID-19 vaccination in Cameroon is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
COVID-19 vaccination in Chad is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
COVID-19 vaccination in Djibouti is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
COVID-19 vaccination in Egypt is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
COVID-19 vaccination in Equatorial Guinea is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
COVID-19 vaccination in Eswatini is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
COVID-19 vaccination in the Central African Republic is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
COVID-19 vaccination in Comoros is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
COVID-19 vaccination in the Democratic Republic of the Congo is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.